A PHP Error was encountered

Severity: 8192

Message: Non-static method Low_search_model::load_models() should not be called statically, assuming $this from incompatible context

Filename: low_search/base.low_search.php

Line Number: 279

A PHP Error was encountered

Severity: 8192

Message: Non-static method Low_title::usage() should not be called statically, assuming $this from incompatible context

Filename: low_title/pi.low_title.php

Line Number: 9

Osteoporosis – Library


Download a quick summary of relevant references


HIV-specific guidelines

Non-HIV-specific guidelines

Key Publications

HIV and osteoporosis

  1. Bolland MJ, Grey AB, Gamble GD, Reid IR. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92:4522–4528.
  2. Jacobson DL, Lindsey JC, Gordon CM, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010;24:687–696.
  3. Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis. 2010;23:1–8.
  4. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937–946.
  5. Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV—a contemporary review. Current opinion in endocrinology, diabetes, and obesity. 2015;22(6):446-451.

ARV therapy and osteoporosis

  1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–2174.
  2. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with non-nucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23:817–824.
  3. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963–972.
  4. van Vonderen MG, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23:1367–1376.
  5. Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Mayer KH, ed. Clin Infect Dis. 2015 Apr 15; 60(8): 1242–1251.
  6. Raffi F, Orkin C, Clarke A, et al. Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017 Mar 6. [Epub ahead of print].

Osteoporosis treatments and HIV

  1. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21:2473–2482.
  2. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83:1135–1141.
  3. Rozenberg S, Lanoy E, Bentata M, et al, and ANRS 120 Fosivir Study Group. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). AIDS Res Hum Retroviruses. 2012 Sep;28(9):972-80.
  4. Pinzone MR, Moreno S, Cacopardo B, Nunnari G. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis. AIDS Rev. 2014 Oct-Dec;16(4):213-22.

Fractures in patients with HIV

  1. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large US healthcare system. J Clin Endocrinol Metab. 2008;93:3499–3504.
  2. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV-infected compared to -uninfected male veterans. PLoS One. 2011;6:e17217.
  3. Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52(8):1061–1068.
  4. Peters BS, Perry M, Wierzbicki AS, et al. A cross-sectional randomised study of fracture risk in people with HIV infection in the Probono 1 study. Polis MA, ed. PLoS ONE. 2013;8(10):e78048.

Patient Resources

AIDS InfoNet: Osteoporosis fact sheet.
AIDSInfo (from the U.S. National Institutes of Health): HIV and Osteoporosis fact sheet.
The Well Project: Bone Health fact sheet.